{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:24:16Z","timestamp":1791890656285,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.ijrobp.2005.06.023","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T11:17:14Z","timestamp":1128079034000},"page":"784-791","source":"Crossref","is-referenced-by-count":162,"title":["Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Andr\u00e9 Deeke","family":"Sasse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Gontijo","family":"de Oliveira Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Chen","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ot\u00e1vio Augusto Camara","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2005.06.023_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0169-5002(03)00078-3","article-title":"Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I\/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone","volume":"40","author":"Jeremic","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(03)01132-X","article-title":"Does amifostine have a role in chemoradiation treatment?","volume":"4","author":"Brizel","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2003.11.005","article-title":"Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable Stage III non-small-cell lung cancer","volume":"21","author":"Leong","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2003.11.008","article-title":"Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer","volume":"30","author":"Antonadou","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/sonc.2002.37349","article-title":"Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma","volume":"29","author":"Bourhis","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2003.11.014","article-title":"Amifostine","volume":"30","author":"Koukourakis","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib8","series-title":"Systematic reviews in health care","author":"Egger","year":"2001"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib11","first-page":"773","article-title":"[Amifostine","volume":"83","author":"Lenoble","year":"1996","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib12","first-page":"984","article-title":"[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors]","volume":"20","author":"Niibe","year":"1985","journal-title":"Nippon Gan Chiryo Gakkai Shi"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib13","first-page":"994","article-title":"[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors]","volume":"20","author":"Niibe","year":"1985","journal-title":"Nippon Gan Chiryo Gakkai Shi"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/50.1.69","article-title":"Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721)","volume":"50","author":"Yuhas","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/sonc.2002.37348","article-title":"Preliminary data of the GORTEC 2000\u201302 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy","volume":"29","author":"Bardet","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1525-1438.1999.99029.x","article-title":"Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix","volume":"9","author":"Gallardo","year":"1999","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib17","first-page":"23","article-title":"Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?","volume":"175","author":"Peters","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/sonc.2002.37346","article-title":"Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer","volume":"29","author":"Anne","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/srao.2002.31374","article-title":"Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer","volume":"12","author":"Antonadou","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1081\/CNV-100000145","article-title":"Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer","volume":"19","author":"Bennett","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s005200050150","article-title":"Radiochemotherapy with amifostine cytoprotection for head and neck cancer","volume":"6","author":"Buntzel","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(92)90527-O","article-title":"Interim analysis of a randomized trial of radiation therapy of rectal cancer with\/without WR-2721","volume":"22","author":"Kligerman","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/srao.2002.31363","article-title":"Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable Stage II-III non-small cell lung cancer","volume":"12","author":"Komaki","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0360-3016(01)01710-2","article-title":"Alteration of radiation-induced hematotoxicity by amifostine","volume":"51","author":"Momm","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib25","first-page":"18","article-title":"[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial]","volume":"175","author":"Vacha","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0360-3016(00)00735-5","article-title":"Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer","volume":"48","author":"Wasserman","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0360-3016(01)01713-8","article-title":"Randomized phase III trial of radiation treatment +\/\u2212 amifostine in patients with advanced-stage lung cancer","volume":"51","author":"Antonadou","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0360-3016(01)02683-9","article-title":"Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer","volume":"52","author":"Antonadou","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0360-3016(03)00590-X","article-title":"Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer","volume":"57","author":"Antonadou","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0360-3016(03)00187-1","article-title":"Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas","volume":"56","author":"Athanassiou","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0360-3016(99)00532-5","article-title":"A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma","volume":"46","author":"Bourhis","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/sonc.2002.37350","article-title":"Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer","volume":"29","author":"Braaksma","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib33","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.2000.18.19.3339","article-title":"Phase III randomized trial of amifostine as a radioprotector in head and neck cancer","volume":"18","author":"Brizel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1023\/A:1008282412670","article-title":"Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer","volume":"9","author":"Buntzel","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.ijrobp.2003.10.005","article-title":"Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer","volume":"58","author":"Komaki","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib36","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.2000.18.11.2226","article-title":"Subcutaneous administration of amifostine during fractionated radiotherapy","volume":"18","author":"Koukourakis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00066-003-0970-y","article-title":"Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors a phase II randomized study using various toxicity scales and rectosigmoidoscopy","volume":"179","author":"Kouvaris","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib38","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/1097-0142(19920601)69:11<2820::AID-CNCR2820691130>3.0.CO;2-T","article-title":"Use of radiation with or without WR-2721 in advanced rectal cancer","volume":"69","author":"Liu","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sonc.2002.37361","article-title":"A phase III randomized evaluation of amifostine in Stage IIIA\/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification","volume":"29","author":"Senzer","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib40","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1200\/JCO.2005.07.167","article-title":"Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation","volume":"23","author":"Movsas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s005200100253","article-title":"Oral health and quality of life among patients with head and neck cancer or haematological malignancies","volume":"9","author":"Ohrn","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib43","first-page":"109","article-title":"Is there a \u201cbest\u201d way to detect and minimize publication bias? An empirical evaluation","volume":"24","author":"Pham","year":"2001","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.ijrobp.2005.06.023_bib44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Stat Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605011545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605011545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T01:53:57Z","timestamp":1548122037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301605011545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0360301605011545"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2005.06.023","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}